两例特发性多中心 Castleman 病伴肾病综合征患者采用托珠单抗治疗。
Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
机构信息
Department of Endocrinology, Metabolism, Rheumatology and Nephrology Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hsama-machi Yufu, Oita, 879-5593, Japan.
Department of Diagnostic Pathology, Faculty of Medicine, Oita University, Oita, Japan.
出版信息
CEN Case Rep. 2021 Feb;10(1):35-41. doi: 10.1007/s13730-020-00511-8. Epub 2020 Jul 26.
Abstract
We report two cases of idiopathic multicentric Castleman disease (iMCD) with nephrotic syndrome (NS) treated with tocilizumab. Case 1 was a 58-year-old man diagnosed with iMCD prior to the onset of NS. Renal biopsy revealed membranous nephropathy, which was considered to be secondary membranous nephropathy associated with iMCD. Case 2 was a 49-year-old woman diagnosed with iMCD prior to NS. Renal biopsy revealed renal amyloidosis positive for Congo red staining and amyloid A protein immunostaining. In both the cases, the proteinuria improved after the initiation of glucocorticoid and tocilizumab therapy. Tocilizumab may be a good therapeutic choice for iMCD with NS.
摘要
我们报告了两例特发性多中心 Castleman 病（iMCD）伴肾病综合征（NS）的病例，均采用托珠单抗治疗。病例 1 为 58 岁男性，在 NS 发病前被诊断为 iMCD。肾活检显示膜性肾病，被认为是与 iMCD 相关的继发性膜性肾病。病例 2 为 49 岁女性，在 NS 发病前被诊断为 iMCD。肾活检显示刚果红染色阳性的肾淀粉样变性和淀粉样 A 蛋白免疫染色。在这两个病例中，蛋白尿在开始使用糖皮质激素和托珠单抗治疗后得到改善。托珠单抗可能是 iMCD 伴 NS 的一种较好的治疗选择。
相似文献
1
Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.两例特发性多中心 Castleman 病伴肾病综合征患者采用托珠单抗治疗。
CEN Case Rep. 2021 Feb;10(1):35-41. doi: 10.1007/s13730-020-00511-8. Epub 2020 Jul 26.
2
Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature.特发性多中心 Castleman 病合并干燥综合征及继发膜性肾病：病例报告及文献复习。
BMC Nephrol. 2020 Dec 4;21(1):528. doi: 10.1186/s12882-020-02191-z.
3
Use of tocilizumab in amyloid a nephropathy associated with Sweet syndrome: a case report and literature review.托珠单抗在 Sweet 综合征相关淀粉样变性肾病中的应用：一例病例报告及文献复习。
CEN Case Rep. 2021 Feb;10(1):23-29. doi: 10.1007/s13730-020-00507-4. Epub 2020 Jul 17.
4
Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease.特立昔珠单抗治疗特发性多中心 Castleman 病伴血栓性微血管病样病变膜性肾病一例
CEN Case Rep. 2021 May;10(2):265-272. doi: 10.1007/s13730-020-00559-6. Epub 2021 Jan 2.
5
Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.托珠单抗在组织学上改善了一名多中心Castleman病患者的AA型肾淀粉样变性：病例报告
Clin Nephrol. 2018 Sep;90(3):232-236. doi: 10.5414/CN109273.
6
Membranous Nephropathy Associated With Multicentric Castleman Disease-Efficacy of Interleukin 6 Antibody for Nephrotic Syndrome.与多中心Castleman病相关的膜性肾病——白细胞介素6抗体对肾病综合征的疗效
J Clin Rheumatol. 2022 Jan 1;28(1):e1-e2. doi: 10.1097/RHU.0000000000001810.
7
Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.与多发性 Castleman 病相关的膜性肾病，经托珠单抗治疗后成功：病例报告及文献复习。
BMC Nephrol. 2021 Jun 9;22(1):216. doi: 10.1186/s12882-021-02423-w.
8
Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.两名 TAFRO 综合征患者的肾活检结果：病例报告及文献复习。
BMC Nephrol. 2020 Nov 23;21(1):499. doi: 10.1186/s12882-020-02119-7.
9
Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series.病例报告：托珠单抗早期持续治疗在特发性多中心Castleman病相关肾病综合征中的重要性：病例系列
Front Med (Lausanne). 2023 Jan 9;9:1037032. doi: 10.3389/fmed.2022.1037032. eCollection 2022.
10
Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.多中心性Castleman病伴继发性AA型肾淀粉样变性、肾病综合征和慢性肾衰竭，经大剂量美法仑和自体干细胞移植后缓解
Clin Nephrol. 2007 Sep;68(3):171-6. doi: 10.5414/cnp68171.
引用本文的文献
1
The Role of Cytokines and Chemokines as Biomarkers of Disease Activity in Idiopathic Nephrotic Syndrome in Children.细胞因子和趋化因子作为儿童特发性肾病综合征疾病活动生物标志物的作用
Curr Issues Mol Biol. 2025 Jan 25;47(2):77. doi: 10.3390/cimb47020077.
2
A Case of Castleman's Disease during the Long-Term Course of Membranous Nephropathy.膜性肾病长期病程中并发Castleman病1例。
Case Rep Nephrol. 2023 Feb 22;2023:4926000. doi: 10.1155/2023/4926000. eCollection 2023.
3
Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series.病例报告：托珠单抗早期持续治疗在特发性多中心Castleman病相关肾病综合征中的重要性：病例系列
Front Med (Lausanne). 2023 Jan 9;9:1037032. doi: 10.3389/fmed.2022.1037032. eCollection 2022.
4
Recovery from AA amyloidosis-cardiomyopathy complexed with unicentric Castleman disease.AA 淀粉样变心肌病合并单中心 Castleman 病的恢复。
BMJ Case Rep. 2022 Aug 18;15(8):e250338. doi: 10.1136/bcr-2022-250338.
5
Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.与多发性 Castleman 病相关的膜性肾病，经托珠单抗治疗后成功：病例报告及文献复习。
BMC Nephrol. 2021 Jun 9;22(1):216. doi: 10.1186/s12882-021-02423-w.
6
Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease.特立昔珠单抗治疗特发性多中心 Castleman 病伴血栓性微血管病样病变膜性肾病一例
CEN Case Rep. 2021 May;10(2):265-272. doi: 10.1007/s13730-020-00559-6. Epub 2021 Jan 2.
7
Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature.特发性多中心 Castleman 病合并干燥综合征及继发膜性肾病：病例报告及文献复习。
BMC Nephrol. 2020 Dec 4;21(1):528. doi: 10.1186/s12882-020-02191-z.
本文引用的文献
1
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.特发性多中心 Castleman 病的新见解和治疗方法。
Blood. 2018 Nov 29;132(22):2323-2330. doi: 10.1182/blood-2018-05-848671.
2
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.特发性多中心 Castleman 病的国际、循证共识治疗指南。
Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.
3
Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy.膜性肾病患者中磷脂酶A2受体及IgG4的表达
Vasc Health Risk Manag. 2018 May 29;14:103-108. doi: 10.2147/VHRM.S160883. eCollection 2018.
4
Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.托珠单抗在组织学上改善了一名多中心Castleman病患者的AA型肾淀粉样变性：病例报告
Clin Nephrol. 2018 Sep;90(3):232-236. doi: 10.5414/CN109273.
5
Treatment of Idiopathic Castleman Disease.特发性Castleman病的治疗
Hematol Oncol Clin North Am. 2018 Feb;32(1):89-106. doi: 10.1016/j.hoc.2017.09.008.
6
Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.托珠单抗（一种抗白细胞介素-6受体的人源化中和抗体）在与Castleman病相关的进行性肾损伤中的疗效。
CEN Case Rep. 2012 May;1(1):7-11. doi: 10.1007/s13730-012-0004-7. Epub 2012 Mar 17.
7
Idiopathic multicentric Castleman's disease: a systematic literature review.特发性多中心Castleman病：一项系统的文献综述
Lancet Haematol. 2016 Apr;3(4):e163-75. doi: 10.1016/S2352-3026(16)00006-5. Epub 2016 Mar 17.
8
Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years.托珠单抗用于多中心Castleman病经类固醇、化疗和利妥昔单抗治疗20多年后的AA型淀粉样变性。
Intern Med. 2015;54(24):3215-9. doi: 10.2169/internalmedicine.54.4183. Epub 2015 Dec 15.
9
Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese.日本M型磷脂酶A2受体（PLA2R）相关膜性肾病的临床病理特征
Clin Exp Nephrol. 2015 Oct;19(5):797-803. doi: 10.1007/s10157-014-1064-0. Epub 2014 Dec 10.
10
Siltuximab for multicentric Castleman disease.司妥昔单抗治疗多中心性Castleman病
Expert Rev Hematol. 2014 Oct;7(5):545-57. doi: 10.1586/17474086.2014.946402. Epub 2014 Aug 9.
Zotero 插件